GlassScriptPhysician profile
Iris Mora Tejeda
NPI 1194446385
$1,930.29
in general payments reported to CMS, 2019-2025
30 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $452 · 2024: $603 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.60 | 2023-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $175.87 | 2023-2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $158.47 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $151.30 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $144.58 | 2023-2025 | |
| Lundbeck LLC | $123.85 | 2024-2025 | Rexulti |
| Abbott Laboratories | $120.21 | 2023-2025 | Freestyle Libre |
| Exact Sciences Corporation | $118.12 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $106.80 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $96.23 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.50 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $43.35 | 2025 | Korlym |
| Calliditas Therapeutics US INC. | $40.38 | 2025 | Tarpeyo |
| Abbvie INC. | $37.23 | 2023-2025 | |
| Dexcom, INC. | $35.31 | 2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $28.18 | 2024 | Crysvita |
| Amgen INC. | $28.05 | 2025 | Repatha |
| Xeris Pharmaceuticals, INC. | $23.48 | 2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $22.30 | 2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $22.17 | 2024 | |
| Cvrx, INC. | $21.39 | 2025 | Barostim Neo System |
| Pfizer INC. | $19.98 | 2023 | |
| Esperion Therapeutics, INC. | $18.69 | 2024 | Nexletol |
| Almatica Pharma LLC | $17.49 | 2023 | Sertraline Hcl, Gralise, Loreev Xr |
| Inspire Medical Systems, INC. | $17.43 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $17.00 | 2024 | Xarelto |
| Ibsa Pharma INC. | $16.63 | 2024 | Licart, Tirosint |
| Akebia Therapeutics INC | $16.07 | 2025 | Vafseo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.07 | 2024 | Xifaxan |
| Evoke Pharma, INC. | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Mora Tejeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.